Alex Edmans

A key economic question in securities litigation is how to determine the amount of harm that can be attributed to alleged misstatements and that may be considered as damages. Securities litigation and the legal frameworks around the determination of damages have been developing in different jurisdictions in Europe over the past ten years.

This white paper provides a brief overview of the classical approach to determining damages that is prevalent in many European jurisdictions; describes the alternative framework called ‘Fraud on the Market’ that has been commonly accepted in US courts; summarizes the evolving state of legal frameworks in some of the leading European jurisdictions; and explains the economics and practicalities of calculating inflation damages.

A key economic question in securities litigation is how to determine the amount of harm that can be attributed to alleged misstatements and that may be considered as damages. Securities litigation and the legal frameworks around the determination of damages have been developing in different jurisdictions in Europe over the past ten years.

This white paper provides a brief overview of the classical approach to determining damages that is prevalent in many European jurisdictions; describes the alternative framework called ‘Fraud on the Market’ that has been commonly accepted in US courts; summarizes the evolving state of legal frameworks in some of the leading European jurisdictions; and explains the economics and practicalities of calculating inflation damages.

Analysis Group was retained on behalf of Reckitt Benckiser, the defendant in a fraud and trade secret misappropriation lawsuit brought by Absorption Pharmaceuticals arising out of a failed acquisition.

Analysis Group was retained on behalf of Reckitt Benckiser, the defendant in a fraud and trade secret misappropriation lawsuit brought by Absorption Pharmaceuticals arising out of a failed acquisition.

An Analysis Group team led by Managing Principals Rebecca Kirk Fair and Emily Cotton was retained by Weil, Gotshal & Manges LLP on behalf of Allergan to provide competitive analyses in support of Allergan’s acquisition by AbbVie.

An Analysis Group team led by Managing Principals Rebecca Kirk Fair and Emily Cotton was retained by Weil, Gotshal & Manges LLP on behalf of Allergan to provide competitive analyses in support of Allergan’s acquisition by AbbVie.

Analysis Group recently helped counsel for the administrator of large defined contribution plans win a dismissal with prejudice in litigation involving allegations that plan participants were being charged excessive fees.

Analysis Group recently helped counsel for the administrator of large defined contribution plans win a dismissal with prejudice in litigation involving allegations that plan participants were being charged excessive fees.